{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:41:08Z","timestamp":1790523668152,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":2746,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1038\/mt.2009.299","type":"journal-article","created":{"date-parts":[[2009,1,27]],"date-time":"2009-01-27T15:29:30Z","timestamp":1233070170000},"page":"632-640","source":"Crossref","is-referenced-by-count":23,"title":["Tolerance Induction Using Lentiviral Gene Delivery Delays Onset and Severity of Collagen II Arthritis"],"prefix":"10.1016","volume":"17","author":[{"given":"Inger","family":"Gjertsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Devitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikard","family":"Holmdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenth","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2009.299_bib1","doi-asserted-by":"crossref","first-page":"e1000024","DOI":"10.1371\/journal.pgen.1000024","article-title":"Defining the role of the MHC in autoimmunity: a review and pooled analysis","volume":"4","author":"Fernando","year":"2008","journal-title":"PLoS Genet"},{"key":"10.1038\/mt.2009.299_bib2","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1073\/pnas.132254199","article-title":"Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis","volume":"99","author":"Backlund","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.299_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/art.1780391015","article-title":"Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression","volume":"39","author":"Cook","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1038\/mt.2009.299_bib4","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4049\/jimmunol.166.3.1492","article-title":"The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis","volume":"166","author":"Corrigall","year":"2001","journal-title":"J Immunol"},{"key":"10.1038\/mt.2009.299_bib5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4049\/jimmunol.169.2.1068","article-title":"Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis","volume":"169","author":"Fritsch","year":"2002","journal-title":"J Immunol"},{"key":"10.1038\/mt.2009.299_bib6","first-page":"177","article-title":"Pattern of humoral reactivity to type II collagen in rheumatoid arthritis","volume":"78","author":"Boissier","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"10.1038\/mt.2009.299_bib7","first-page":"281","article-title":"Autoantigens and immune pathways in rheumatoid arthritis","volume":"22","author":"Corrigall","year":"2002","journal-title":"Crit Rev Immunol"},{"key":"10.1038\/mt.2009.299_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000441-200404000-00006","article-title":"Type II collagen autoimmunity in rheumatoid arthritis","volume":"327","author":"Kim","year":"2004","journal-title":"Am J Med Sci"},{"key":"10.1038\/mt.2009.299_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/jaut.2001.0569","article-title":"The influence of HLA-DR4 (0401) on the immune response to type II collagen and the development of collagen induced arthritis in mice","volume":"18","author":"Wang","year":"2002","journal-title":"J Autoimmun"},{"key":"10.1038\/mt.2009.299_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.autrev.2007.08.001","article-title":"Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis","volume":"7","author":"Cho","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1038\/mt.2009.299_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.immuni.2008.03.005","article-title":"Cytokines as therapeutic targets: advances and limitations","volume":"28","author":"Scheinecker","year":"2008","journal-title":"Immunity"},{"key":"10.1038\/mt.2009.299_bib12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4049\/jimmunol.177.1.290","article-title":"Lymphotoxin pathway-directed, autoimmune regulator-independent central tolerance to arthritogenic collagen","volume":"177","author":"Chin","year":"2006","journal-title":"J Immunol"},{"key":"10.1038\/mt.2009.299_bib13","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1126\/science.8378772","article-title":"Effects of oral administration of type II collagen on rheumatoid arthritis","volume":"261","author":"Trentham","year":"1993","journal-title":"Science"},{"key":"10.1038\/mt.2009.299_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/1529-0131(199802)41:2<290::AID-ART13>3.0.CO;2-R","article-title":"Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial","volume":"41","author":"Barnett","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1038\/mt.2009.299_bib15","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/1529-0131(200109)44:9<1993::AID-ART347>3.0.CO;2-A","article-title":"Control of rheumatoid arthritis by oral tolerance","volume":"44","author":"Choy","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1038\/mt.2009.299_bib16","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1073\/pnas.83.19.7443","article-title":"Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen","volume":"83","author":"Nagler-Anderson","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.299_bib17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/1529-0131(199908)42:8<1628::AID-ANR10>3.0.CO;2-T","article-title":"Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine","volume":"42","author":"Tarkowski","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1038\/mt.2009.299_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4049\/jimmunol.168.1.253","article-title":"HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen","volume":"168","author":"Rosloniec","year":"2002","journal-title":"J Immunol"},{"key":"10.1038\/mt.2009.299_bib19","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1073\/pnas.95.13.7574","article-title":"Definition of MHC and T cell receptor contacts in the HLA-DR4 restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice","volume":"95","author":"Andersson","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.299_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1074-7613(00)80369-6","article-title":"X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II","volume":"7","author":"Dessen","year":"1997","journal-title":"Immunity"},{"key":"10.1038\/mt.2009.299_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s002510050461","article-title":"Human collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis","volume":"49","author":"Diab","year":"1999","journal-title":"Immunogenetics"},{"key":"10.1038\/mt.2009.299_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<755::AID-IMMU755>3.0.CO;2-2","article-title":"The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules","volume":"28","author":"Kjellen","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1038\/mt.2009.299_bib23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/eji.1830220722","article-title":"Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection","volume":"22","author":"Michaelsson","year":"1992","journal-title":"Eur J Immunol"},{"key":"10.1038\/mt.2009.299_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/cimm.1996.0210","article-title":"Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis","volume":"172","author":"Rosloniec","year":"1996","journal-title":"Cell Immunol"},{"key":"10.1038\/mt.2009.299_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0167-5699(00)01717-5","article-title":"Hijacking a chaperone: manipulation of the MHC class II presentation pathway","volume":"21","author":"Koch","year":"2000","journal-title":"Immunol Today"},{"key":"10.1038\/mt.2009.299_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0198-8859(98)00058-5","article-title":"The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells","volume":"59","author":"Fujii","year":"1998","journal-title":"Hum Immunol"},{"key":"10.1038\/mt.2009.299_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1021074613196","article-title":"HIV-1 vector systems","volume":"26","author":"Srinivasakumar","year":"2001","journal-title":"Somat Cell Mol Genet"},{"key":"10.1038\/mt.2009.299_bib28","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2580::AID-IMMU2580>3.0.CO;2-X","article-title":"Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis","volume":"28","author":"Corthay","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1038\/mt.2009.299_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/jaut.1999.0320","article-title":"Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen","volume":"13","author":"Garcia","year":"1999","journal-title":"J Autoimmun"},{"key":"10.1038\/mt.2009.299_bib30","first-page":"1038","article-title":"Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis","volume":"27","author":"Higuchi","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1038\/mt.2009.299_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/intimm\/dxh075","article-title":"Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis","volume":"16","author":"Honda","year":"2004","journal-title":"Int Immunol"},{"key":"10.1038\/mt.2009.299_bib32","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.4049\/jimmunol.155.7.3653","article-title":"Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis","volume":"155","author":"Khare","year":"1995","journal-title":"J Immunol"},{"key":"10.1038\/mt.2009.299_bib33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2249.1996.tb08289.x","article-title":"Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope","volume":"103","author":"Staines","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1038\/mt.2009.299_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clim.2006.08.004","article-title":"Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis","volume":"122","author":"Zhu","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1038\/mt.2009.299_bib35","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4049\/jimmunol.176.3.1525","article-title":"Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules","volume":"176","author":"Dzhambazov","year":"2006","journal-title":"J Immunol"},{"key":"10.1038\/mt.2009.299_bib36","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/art.21886","article-title":"Gene therapy for arthritis: what next?","volume":"54","author":"Evans","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1038\/mt.2009.299_bib37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/kel047","article-title":"Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes","volume":"45","author":"Adriaansen","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1038\/mt.2009.299_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/mthe.2002.0630","article-title":"Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow","volume":"6","author":"Pan","year":"2002","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.299_bib39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.autrev.2005.01.007","article-title":"Regulatory T cells: development, function and role in autoimmunity","volume":"4","author":"Lan","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1038\/mt.2009.299_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-\u03b2 regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/mt.2009.299_bib41","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1073\/pnas.89.16.7375","article-title":"Involvement of endogenous tumor necrosis factor alpha and transforming growth factor \u03b2 during induction of collagen type II arthritis in mice","volume":"89","author":"Thorbecke","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.299_bib42","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.0608138103","article-title":"Gene transfer in humans using a conditionally replicating lentiviral vector","volume":"103","author":"Levine","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.299_bib43","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/10430340252898984","article-title":"High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter","volume":"13","author":"Demaison","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2009.299_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00011-003-1182-8","article-title":"Genistein as an anti-inflammatory agent","volume":"52","author":"Verdrengh","year":"2003","journal-title":"Inflamm Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616315568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616315568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T15:58:15Z","timestamp":1709999895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616315568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1525001616315568"],"URL":"https:\/\/doi.org\/10.1038\/mt.2009.299","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}